Genotype-phenotype correlations in Fanconi anemia

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 668, Issue 1-2, 2009, Pages 73-91

  Neveling, Kornelia ^a   Endt, Daniela ^a   Hoehn, Holger ^a   Schindler, Detlev ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Accelerated ageing; Bone marrow failure; Cancer susceptibility; DNA repair; Fanconi anemia; Genome instability; Genotype phenotype correlations; Mechanisms of ageing; Segmental progeroid syndromes; Stem cells

Indexed keywords

BRCA2 PROTEIN; DNA; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; RAD51 PROTEIN;

APOPTOSIS; CANCER RISK; CELL CYCLE PROGRESSION; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; DNA CROSS LINKING; ENVIRONMENTAL FACTOR; FANCONI ANEMIA; GENE MUTATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; MOSAICISM; NONHUMAN; PANCYTOPENIA; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGERIA; REVERTANT; REVIEW; SURVIVAL RATE;

AGING; APOPTOSIS; CELL CYCLE; CHROMOSOME ABERRATIONS; CROSS-LINKING REAGENTS; DNA REPAIR; FANCONI ANEMIA; GENOMIC INSTABILITY; GENOTYPE; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; PROGERIA; RAD51 RECOMBINASE;

EID: 67650403821     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.05.006     Document Type: Review

References (198)

1. Giampietro P.F., Verlander P.C., Davis J.G., and Auerbach A.D. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am. J. Med. Genet. 68 (1997) 58-61
2. Faivre L., Guardiola P., Lewis C., Dokal I., Ebell W., Zatterale A., Altay C., Poole J., Stones D., Kwee M.L., van Weel-Sipman M., Havenga C., Morgan N., de Winter J., Digweed M., Savoia A., Pronk J., de Ravel T., Jansen S., Joenje H., Gluckman E., and Mathew C.G. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group. Blood 96 (2000) 4064-4070
3. Kutler D.I., Singh B., Satagopan J., Batish S.D., Berwick M., Giampietro P.F., Hanenberg H., and Auerbach A.D. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101 (2003) 1249-1256
4. Alter B.P. The association between FANCD1/BRCA2 mutations and leukaemia. Br. J. Haematol. 133 (2006) 446-448 author reply 448
5. Rosenberg P.S., Huang Y., and Alter B.P. Individualized risks of first adverse events in patients with Fanconi anemia. Blood 104 (2004) 350-355
6. Rosenberg P.S., Alter B.P., and Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 93 (2008) 511-517
7. Human genome variation society. Nomenclature for the description of sequence variations, http://www.hgvs.org/mutnomen/.
8. Kutler D.I., and Auerbach A.D. Fanconi anemia in Ashkenazi Jews. Fam. Cancer 3 (2004) 241-248
9. Futaki M., Yamashita T., Yagasaki H., Toda T., Yabe M., Kato S., Asano S., and Nakahata T. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood 95 (2000) 1493-1498
10. Davies S.M., Radloff G.A., DeFor T.E., Levran O., Batish S.D., Hanenberg H., and Auerbach A.D. GST genotype may modify clinical phenotype in patients with Fanconi anaemia. Br. J. Haematol. 131 (2005) 118-122
11. Auerbach A.D., Rogatko A., and Schroeder-Kurth T.M. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73 (1989) 391-396
12. Morales J.F., Song T., Auerbach A.D., and Wittkowski K.M. Phenotyping genetic diseases using an extension of micro-scores for multivariate data. Stat. Appl. Genet. Mol. Biol. 7 (2008) Article 19
13. Faivre L., Collod-Beroud G., Loeys B.L., Child A., Binquet C., Gautier E., Callewaert B., Arbustini E., Mayer K., Arslan-Kirchner M., Kiotsekoglou A., Comeglio P., Marziliano N., Dietz H.C., Halliday D., Beroud C., Bonithon-Kopp C., Claustres M., Muti C., Plauchu H., Robinson P.N., Ades L.C., Biggin A., Benetts B., Brett M., Holman K.J., De Backer J., Coucke P., Francke U., De Paepe A., Jondeau G., and Boileau C. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am. J. Hum. Genet. 81 (2007) 454-466
14. Lampe A.K., Zou Y., Sudano D., O'Brien K.K., Hicks D., Laval S.H., Charlton R., Jimenez-Mallebrera C., Zhang R.Z., Finkel R.S., Tennekoon G., Schreiber G., van der Knaap M.S., Marks H., Straub V., Flanigan K.M., Chu M.L., Muntoni F., Bushby K.M., and Bonnemann C.G. Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum. Mutat. 29 (2008) 809-822
15. Hegele R. LMNA mutation position predicts organ system involvement in laminopathies. Clin. Genet. 68 (2005) 31-34
16. Schroeder T.M., Anschutz F., and Knopp A. Spontaneous chromosome aberrations in familial panmyelopathy. Humangenetik 1 (1964) 194-196
17. Joenje H., Arwert F., Eriksson A.W., de Koning H., and Oostra A.B. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 290 (1981) 142-143
18. Poot M., Gross O., Epe B., Pflaum M., and Hoehn H. Cell cycle defect in connection with oxygen and iron sensitivity in Fanconi anemia lymphoblastoid cells. Exp. Cell. Res. 222 (1996) 262-268
19. Schindler D., and Hoehn H. Fanconi anemia mutation causes cellular susceptibility to ambient oxygen. Am. J. Hum. Genet. 43 (1988) 429-435
20. Alter B.P., Knobloch M.E., and Weinberg R.S. Erythropoiesis in Fanconi's anemia. Blood 78 (1991) 602-608
21. Cohen-Haguenauer O., Peault B., Bauche C., Daniel M.T., Casal I., Levy V., Dausset J., Boiron M., Auclair C., Gluckman E., and Marty M. In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 2340-2345
22. Kalb R., Duerr M., Wagner M., Herterich S., Gross M., Digweed M., Joenje H., Hoehn H., and Schindler D. Lack of sensitivity of primary Fanconi's anemia fibroblasts to UV and ionizing radiation. Radiat. Res. 161 (2004) 318-325
23. Niedernhofer L.J., Garinis G.A., Raams A., Lalai A.S., Robinson A.R., Appeldoorn E., Odijk H., Oostendorp R., Ahmad A., van Leeuwen W., Theil A.F., Vermeulen W., van der Horst G.T., Meinecke P., Kleijer W.J., Vijg J., Jaspers N.G., and Hoeijmakers J.H. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444 (2006) 1038-1043
24. Jaspers N.G., Raams A., Silengo M.C., Wijgers N., Niedernhofer L.J., Robinson A.R., Giglia-Mari G., Hoogstraten D., Kleijer W.J., Hoeijmakers J.H., and Vermeulen W. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am. J. Hum. Genet. 80 (2007) 457-466
25. Schmid W., Scharer K., Baumann T., and Fanconi G. Chromosal fragility in familial panmyelopathy (Fanconi type). Schweiz Med Wochenschr 95 (1965) 1461-1464
26. Meetei A.R., Sechi S., Wallisch M., Yang D., Young M.K., Joenje H., Hoatlin M.E., and Wang W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol. Cell. Biol. 23 (2003) 3417-3426
27. Newell A.E., Akkari Y.M., Torimaru Y., Rosenthal A., Reifsteck C.A., Cox B., Grompe M., and Olson S.B. Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes. DNA Repair (Amst.) 3 (2004) 535-542
28. Tutt A., Bertwistle D., Valentine J., Gabriel A., Swift S., Ross G., Griffin C., Thacker J., and Ashworth A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20 (2001) 4704-4716
29. Nakanishi K., Yang Y.G., Pierce A.J., Taniguchi T., Digweed M., D'Andrea A.D., Wang Z.Q., and Jasin M. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1110-1115
30. Shiraishi Y. Nature and role of high sister chromatid exchanges in Bloom syndrome cells. Some cytogenetic and immunological aspects. Cancer Genet. Cytogenet. 50 (1990) 175-187
31. Yamazoe M., Sonoda E., Hochegger H., and Takeda S. Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair (Amst.) 3 (2004) 1175-1185
32. Freie B., Li X., Ciccone S.L., Nawa K., Cooper S., Vogelweid C., Schantz L., Haneline L.S., Orazi A., Broxmeyer H.E., Lee S.H., and Clapp D.W. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102 (2003) 4146-4152
33. Ball S.E., Gibson F.M., Rizzo S., Tooze J.A., Marsh J.C., and Gordon-Smith E.C. Progressive telomere shortening in aplastic anemia. Blood 91 (1998) 3582-3592
34. Leteurtre F., Li X., Guardiola P., Le Roux G., Sergere J.C., Richard P., Carosella E.D., and Gluckman E. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br. J. Haematol. 105 (1999) 883-893
35. Hanson H., Mathew C.G., Docherty Z., and Mackie Ogilvie C. Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. Cytogenet. Cell Genet. 93 (2001) 203-206
36. Adelfalk C., Lorenz M., Serra V., von Zglinicki T., Hirsch-Kauffmann M., and Schweiger M. Accelerated telomere shortening in Fanconi anemia fibroblasts-a longitudinal study. FEBS Lett. 506 (2001) 22-26
37. Callen E., Samper E., Ramirez M.J., Creus A., Marcos R., Ortega J.J., Olive T., Badell I., Blasco M.A., and Surralles J. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum. Mol. Genet. 11 (2002) 439-444
38. Callen E., and Surralles J. Telomere dysfunction in genome instability syndromes. Mutat. Res. 567 (2004) 85-104
39. Franco S., van de Vrugt H.J., Fernandez P., Aracil M., Arwert F., and Blasco M.A. Telomere dynamics in Fancg-deficient mouse and human cells. Blood 104 (2004) 3927-3935
40. Neitzel H., Kühl J.S., Gerlach A., Ebell W., and Tönnies H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: results and implications. In: Hoehn H., and Schindler D. (Eds). Fanconi Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging (2007), Karger, Basel 79-94
41. Tonnies H., Huber S., Kuhl J.S., Gerlach A., Ebell W., and Neitzel H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 101 (2003) 3872-3874
42. Meyer S., Fergusson W.D., Whetton A.D., Moreira-Leite F., Pepper S.D., Miller C., Saunders E.K., White D.J., Will A.M., Eden T., Ikeda H., Ullmann R., Tuerkmen S., Gerlach A., Klopocki E., and Tonnies H. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. Genes Chromosomes Cancer 46 (2007) 359-372
43. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396 (2007) 346-357
44. Sasaki M.S., and Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res. 33 (1973) 1829-1836
45. Auerbach A.D. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp. Hematol. 21 (1993) 731-733
46. Schroeder-Kurth T.M., Zhu T.H., Hong Y., and Westphal I. Variation in cellular sensitivities among Fanconi anemia patients, non-Fanconi anemia patients, their parents and siblings, and control probands. In: Auerbach A.D., Schroeder-Kurth T.M., and Obe G. (Eds). Fanconi Anemia. Clinical, Cytogenetic and Experimental Aspects (1989), Springer Verlag, Berlin, Germany p. 105
47. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., Oostra A.B., Veerman A.J., van Weel M., Pauli R.M., Shahidi N.T., Dokal I., Roberts I., Altay C., Gluckman E., Gibson R.A., Mathew C.G., Arwert F., and Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur. J. Hum. Genet. 5 (1997) 137-148
48. Seyschab H., Friedl R., Sun Y., Schindler D., Hoehn H., Hentze S., and Schroeder-Kurth T. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 85 (1995) 2233-2237
49. Heinrich M.C., Hoatlin M.E., Zigler A.J., Silvey K.V., Bakke A.C., Keeble W.W., Zhi Y., Reifsteck C.A., Grompe M., Brown M.G., Magenis R.E., Olson S.B., and Bagby G.C. DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 91 (1998) 275-287
50. Chandra S., Levran O., Jurickova I., Maas C., Kapur R., Schindler D., Henry R., Milton K., Batish S.D., Cancelas J.A., Hanenberg H., Auerbach A.D., and Williams D.A. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol. Ther. 12 (2005) 976-984
51. Casado A.J., Callen E., Jacome A., Rio P., Castella M., Lobitz S., Ferro T., Munoz A., Sevilla J., Cantalejo A., Cela E., Cervera J., Sanchez-Calero J., Badell I., Estella J., Dasi A., Olive T., Jose Ortega J., Rodriguez-Villa A., Tapia M., Molines A., Madero L., Segovia J.C., Neveling K., Kalb R., Schindler D., Hanenberg H., Surralles J., and Bueren J.A. A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. J. Med. Genet. 44 (2007) 241-249
52. Adachi D., Oda T., Yagasaki H., Nakasato K., Taniguchi T., D'Andrea A.D., Asano S., and Yamashita T. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. Hum. Mol. Genet. 11 (2002) 3125-3134
53. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 8 (2007) 735-748
54. Digweed M., Demuth I., Rothe S., Scholz R., Jordan A., Grotzinger C., Schindler D., Grompe M., and Sperling K. SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene 21 (2002) 4873-4878
55. Ameziane N., Errami A., Leveille F., Fontaine C., de Vries Y., van Spaendonk R.M., de Winter J.P., Pals G., and Joenje H. Genetic subtyping of Fanconi anemia by comprehensive mutation screening. Hum. Mutat. 29 (2007) 159-166
56. Hanenberg H., Batish S.D., Pollok K.E., Vieten L., Verlander P.C., Leurs C., Cooper R.J., Gottsche K., Haneline L., Clapp D.W., Lobitz S., Williams D.A., and Auerbach A.D. Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp. Hematol. 30 (2002) 410-420
57. Reid S., Schindler D., Hanenberg H., Barker K., Hanks S., Kalb R., Neveling K., Kelly P., Seal S., Freund M., Wurm M., Batish S.D., Lach F.P., Yetgin S., Neitzel H., Ariffin H., Tischkowitz M., Mathew C.G., Auerbach A.D., and Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39 (2007) 162-164
58. Gennery A.R., Slatter M.A., Bhattacharya A., Barge D., Haigh S., O'Driscoll M., Coleman R., Abinun M., Flood T.J., Cant A.J., and Jeggo P.A. The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia. Clin. Immunol. 113 (2004) 214-219
59. New H.V., Cale C.M., Tischkowitz M., Jones A., Telfer P., Veys P., D'Andrea A., Mathew C.G., and Hann I. Nijmegen breakage syndrome diagnosed as Fanconi anaemia. Pediatr. Blood Cancer 44 (2005) 494-499
60. Bakhshi S., Joenje H., Schindler D., Oostra A., Mohamed A.N., Madgy D., Ravindranath Y., and Abella E. A case report of a patient with microcephaly, facial dysmorphism, mitomycin-c-sensitive lymphocytes, and susceptibility to lymphoma. Cancer Genet. Cytogenet. 164 (2006) 168-171
61. Andreassen P.R., D'Andrea A.D., and Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18 (2004) 1958-1963
62. Vrouwe M.G., Elghalbzouri-Maghrani E., Meijers M., Schouten P., Godthelp B.C., Bhuiyan Z.A., Redeker E.J., Mannens M.M., Mullenders L.H., Pastink A., and Darroudi F. Increased DNA damage sensitivity of Cornelia de Lange syndrome cells: evidence for impaired recombinational repair. Hum. Mol. Genet. 16 (2007) 1478-1487
63. Nakanishi K., Taniguchi T., Ranganathan V., New H.V., Moreau L.A., Stotsky M., Mathew C.G., Kastan M.B., Weaver D.T., and D'Andrea A.D. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4 (2002) 913-920
64. Djuzenova C.S., Schindler D., Stopper H., Hoehn H., Flentje M., and Oppitz U. Identification of ataxia telangiectasia heterozygotes, a cancer-prone population, using the single-cell gel electrophoresis (Comet) assay. Lab. Invest 79 (1999) 699-705
65. Djuzenova C.S., and Flentje M. Characterization of Fanconi anemia fibroblasts in terms of clonogenic survival and DNA damage assessed by the Comet assay. Med. Sci. Monit. 8 (2002) BR421-430
66. Henson S.E., Tsai S.C., Malone C.S., Soghomonian S.V., Ouyang Y., Wall R., Marahrens Y., and Teitell M.A. Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks. Mutat. Res. 601 (2006) 113-124
67. Mirchandani K.D., McCaffrey R.M., and D'Andrea A.D. The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst.) 7 (2008) 902-911
68. Hejna J., Holtorf M., Hines J., Mathewson L., Hemphill A., Al-Dhalimy M., Olson S.B., and Moses R.E. Tip60 is required for DNA interstrand cross-link repair in the Fanconi anemia pathway. J. Biol. Chem. 283 (2008) 9844-9851
69. Bae J.B., Mukhopadhyay S.S., Liu L., Zhang N., Tan J., Akhter S., Liu X., Shen X., Li L., and Legerski R.J. Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links. Oncogene 27 (2008) 5045-5056
70. Ling C., Ishiai M., Ali A.M., Medhurst A.L., Neveling K., Kalb R., Yan Z., Xue Y., Oostra A.B., Auerbach A.D., Hoatlin M.E., Schindler D., Joenje H., de Winter J.P., Takata M., Meetei A.R., and Wang W. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 26 (2007) 2104-2114
71. Neveling K., Kalb R., and Schindler D. Cancer in Fanconi anemia and Fanconi anemia genes in cancer. In: Hoehn H., and Schindler D. (Eds). Fanconi Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging (2007), Karger, Basel 59-78
72. Gallmeier E., and Kern S.E. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin. Cancer Res. 13 (2007) 4-10
73. Chirnomas D., Taniguchi T., de la Vega M., Vaidya A.P., Vasserman M., Hartman A.R., Kennedy R., Foster R., Mahoney J., Seiden M.V., and D'Andrea A.D. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5 (2006) 952-961
74. Gallmeier E., Calhoun E.S., Rago C., Brody J.R., Cunningham S.C., Hucl T., Gorospe M., Kohli M., Lengauer C., and Kern S.E. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 130 (2006) 2145-2154
75. Ferrer M., de Winter J.P., Mastenbroek D.C., Curiel D.T., Gerritsen W.R., Giaccone G., and Kruyt F.A. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther. 11 (2004) 539-546
76. Kasai H., Iwamoto-Tanaka N., and Fukada S. DNA modifications by the mutagen glyoxal: adduction to G and C, deamination of C and GC and GA cross-linking. Carcinogenesis 19 (1998) 1459-1465
77. Niedernhofer L.J., Daniels J.S., Rouzer C.A., Greene R.E., Marnett L.J., and Malondialdehyde. a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem. 278 (2003) 31426-31433
78. Ellul A., Povey A., and O'Neill I.K. Presence of endogenous cross-linking/bifunctional agents in gastrointestinal cavity as detected by transit of magnetic PEI microcapsules. Carcinogenesis 11 (1990) 1577-1582
79. Dutrillaux B., Aurias A., Dutrillaux A.M., Buriot D., and Prieur M. The cell cycle of lymphocytes in Fanconi anemia. Hum. Genet. 62 (1982) 327-332
80. Kubbies M., Schindler D., Hoehn H., Schinzel A., and Rabinovitch P.S. Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent edomitosis in Fanconi anemia cells. Am. J. Hum. Genet. 37 (1985) 1022-1030
81. Rabinovitch P.S., Kubbies M., Chen Y.C., Schindler D., and Hoehn H. BrdU-Hoechst flow cytometry: a unique tool for quantitative cell cycle analysis. Exp. Cell. Res. 174 (1988) 309-318
82. Rabinovitch P.S. Regulation of human fibroblast growth rate by both noncycling cell fraction transition probability is shown by growth in 5-bromodeoxyuridine followed by Hoechst 33258 flow cytometry. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 2951-2955
83. Schindler D., Friedl R., Gavvovidis I., Kalb R., Neveling K., Linka Y., Hanenberg H., Kubbies M., and Hoehn H. Applications of cell cycle testing in Fanconi anemia. In: Hoehn H., and Schindler D. (Eds). Fanconi Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging (2007), Karger, Basel 110-130
84. Akkari Y.M., Bateman R.L., Reifsteck C.A., D'Andrea A.D., Olson S.B., and Grompe M. The 4n cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol. Genet. Metab. 74 (2001) 403-412
85. Kaiser T.N., Lojewski A., Dougherty C., Juergens L., Sahar E., and Latt S.A. Flow cytometric characterization of the response of Fanconi's anemia cells to mitomycin C treatment. Cytometry 2 (1982) 291-297
86. Berger R., Le Coniat M., and Gendron M.C. Fanconi anemia. Chromosome breakage and cell cycle studies. Cancer Genet. Cytogenet. 69 (1993) 13-16
87. Sala-Trepat M., Rouillard D., Escarceller M., Laquerbe A., Moustacchi E., and Papadopoulo D. Arrest of S-phase progression is impaired in Fanconi anemia cells. Exp. Cell. Res. 260 (2000) 208-215
88. Godthelp B.C., van Buul P.P., Jaspers N.G., Elghalbzouri-Maghrani E., van Duijn-Goedhart A., Arwert F., Joenje H., and Zdzienicka M.Z. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Mutat. Res. 601 (2006) 191-201
89. Centurion S.A., Kuo H.R., and Lambert W.C. Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent. Exp. Cell. Res. 260 (2000) 216-221
90. Guervilly J.H., Mace-Aime G., and Rosselli F. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum. Mol. Genet. 17 (2008) 679-689
91. Seyschab H., Sun Y., Friedl R., Schindler D., and Hoehn H. G2 phase cell cycle disturbance as a manifestation of genetic cell damage. Hum. Genet. 92 (1993) 61-68
92. Johnstone P., Reifsteck C., Kohler S., Worland P., Olson S., and Moses R.E. Fanconi anemia group A and D cell lines respond normally to inhibitors of cell cycle regulation. Somat. Cell. Mol. Genet. 23 (1997) 371-377
93. Sabatier L., and Dutrillaux B. Effect of caffeine in Fanconi anemia. I. Restoration of a normal duration of G2 phase. Hum. Genet. 79 (1988) 242-244
94. Seyschab H., Bretzel G., Friedl R., Schindler D., Sun Y., and Hoehn H. Modulation of the spontaneous G2 phase blockage in Fanconi anemia cells by caffeine: differences from cells arrested by X-irradiation. Mutat. Res. 308 (1994) 149-157
95. Kupfer G.M., and D'Andrea A.D. The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. Blood 88 (1996) 1019-1025
96. Casado J.A., Rio P., Marco E., Garcia-Hernandez V., Domingo A., Perez L., Tercero J.C., Vaquero J.J., Albella B., Gago F., and Bueren J.A. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol. Cancer Ther. 7 (2008) 1309-1318
97. Saito H., Hammond A.T., and Moses R.E. Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. Mutat. Res. 294 (1993) 255-262
98. Hoehn H., Kubbies M., Schindler D., Poot M., and Rabinovitch P.S. BrdU-Hoechst flow cytometry links the cell kinetic defect of Fanconi anemia to oxygen hypersensitivity. In: Auerbach A.D., Schroeder-Kurth T.M., and Obe G. (Eds). Fanconi Anemia: Clinical, Cytogenetic and Experimental Aspects (1989), Springer, Berlin 161-173
99. Liebetrau W., Runge T.M., Baumer A., Henning C., Gross O., Schindler D., Poot M., and Hoehn H. Exploring the role of oxygen in Fanconi's anemia. Recent Results Cancer Res. 143 (1997) 353-367
100. Liebetrau W., Runger T.M., Mehling B.E., Poot M., and Hoehn H. Mutagenic activity of ambient oxygen and mitomycin C in Fanconi's anaemia cells. Mutagenesis 12 (1997) 69-77
101. Jang Y.Y., and Sharkis S.J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110 (2007) 3056-3063
102. Naka K., Muraguchi T., Hoshii T., and Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid. Redox Signal. 10 (2008) 1883-1894
103. Du W., Adam Z., Rani R., Zhang X., and Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid. Redox Signal. 10 (2008) 1909-1921
104. Pagano G., Degan P., d'Ischia M., Kelly F.J., Nobili B., Pallardo F.V., Youssoufian H., and Zatterale A. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur. J. Haematol. 75 (2005) 93-100
105. Reuter T.Y., Medhurst A.L., Waisfisz Q., Zhi Y., Herterich S., Hoehn H., Gross H.J., Joenje H., Hoatlin M.E., Mathew C.G., and Huber P.A. Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport. Exp. Cell. Res. 289 (2003) 211-221
106. Clarke A.A., Gibson F.M., Scott J., Myatt N., and Rutherford T.R. Fanconi's anemia cell lines show distinct mechanisms of cell death in response to mitomycin C or agonistic anti-Fas antibodies. Haematologica 89 (2004) 11-20
107. Mukhopadhyay S.S., Leung K.S., Hicks M.J., Hastings P.J., Youssoufian H., and Plon S.E. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J. Cell. Biol. 175 (2006) 225-235
108. Carreau M., Alon N., Bosnoyan-Collins L., Joenje H., and Buchwald M. Drug sensitivity spectra in Fanconi anemia lymphoblastoid cell lines of defined complementation groups. Mutat. Res. 435 (1999) 103-109
109. Bijangi-Vishehsaraei K., Saadatzadeh M.R., Werne A., McKenzie K.A., Kapur R., Ichijo H., and Haneline L.S. Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1. Blood 106 (2005) 4124-4130
110. -/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood 105 (2005) 3465-3471
111. Dufour C., Corcione A., Svahn J., Haupt R., Poggi V., Beka'ssy A.N., Scime R., Pistorio A., and Pistoia V. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102 (2003) 2053-2059
112. Otsuki T., Nagakura S., Wang J., Bloom M., Grompe M., and Liu J.M. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J. Cell. Physiol. 179 (1999) 79-86
113. Wang J., Otsuki T., Youssoufian H., Foe J.L., Kim S., Devetten M., Yu J., Li Y., Dunn D., and Liu J.M. Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res. 58 (1998) 3538-3541
114. Schultz J.C., and Shahidi N.T. Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am. J. Hematol. 42 (1993) 196-201
115. Ridet A., Guillouf C., Duchaud E., Cundari E., Fiore M., Moustacchi E., and Rosselli F. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Cancer Res. 57 (1997) 1722-1730
116. Guillouf C., Wang T.S., Liu J., Walsh C.E., Poirier G.G., Moustacchi E., and Rosselli F. Fanconi anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-induced cell death. Exp. Cell. Res. 246 (1999) 384-394
117. Liu T.X., Howlett N.G., Deng M., Langenau D.M., Hsu K., Rhodes J., Kanki J.P., D'Andrea A.D., and Look A.T. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev. Cell 5 (2003) 903-914
118. Sii-Felice K., Barroca V., Etienne O., Riou L., Hoffschir F., Fouchet P., Boussin F.D., and Mouthon M.A. Role of fanconi DNA repair pathway in neural stem cell homeostasis. Cell Cycle 7 (2008) 1911-1915
119. Haaf T., Golub E.I., Reddy G., Radding C.M., and Ward D.C. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2298-2302
120. Tashiro S., Walter J., Shinohara A., Kamada N., and Cremer T. Rad51 accumulation at sites of DNA damage and in postreplicative chromatin. J. Cell. Biol. 150 (2000) 283-291
121. Digweed M., Rothe S., Demuth I., Scholz R., Schindler D., Stumm M., Grompe M., Jordan A., and Sperling K. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 23 (2002) 1121-1126
122. Godthelp B.C., Wiegant W.W., Waisfisz Q., Medhurst A.L., Arwert F., Joenje H., and Zdzienicka M.Z. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat. Res. 594 (2006) 39-48
123. Tsuchida K., and Komatsu K. Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group. Cancer Sci. 99 (2008) 2238-2243
124. Alter B.P., Rosenberg P.S., and Brody L.C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J. Med. Genet. 44 (2007) 1-9
125. Hoehn H., Kalb R., Neveling K., Friedl R., Bechtold A., Herterich S., Sun Y., Gruhn B., Hanenberg H., and Schindler D. Revertant mosaicism in Fanconi anemia: natural gene therapy at work. In: Hoehn H., and Schindler D. (Eds). Fanconi Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging (2007), Karger, Basel 149-172
126. Frappart P.O., Lee Y., Lamont J., and McKinnon P.J. BRCA2 is required for neurogenesis and suppression of medulloblastoma. EMBO J. 26 (2007) 2732-2742
127. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 7 (2007) 152
128. Landmann E., Bluetters-Sawatzki R., Schindler D., and Gortner L. Fanconi anemia in a neonate with pancytopenia. J. Pediatr. 145 (2004) 125-127
129. Kwee M.L., van der Kleij J.M., van Essen A.J., Begeer J.H., Joenje H., Arwert F., and ten Kate L.P. An atypical case of Fanconi anemia in elderly sibs. Am. J. Med. Genet. 68 (1997) 362-366
130. Koc A., Pronk J.C., Alikasifoglu M., Joenje H., and Altay C. Variable pathogenicity of exon 43del (FAA) in four Fanconi anaemia patients within a consanguineous family. Br. J. Haematol. 104 (1999) 127-130
131. Schoof E., Beck J.D., Joenje H., and Doerr H.G. Growth hormone deficiency in one of two siblings with Fanconi's anaemia complementation group FA-D. Growth Horm. IGF Res. 10 (2000) 290-294
132. Dietrich R., and Velleuer E. Fanconi anemia: a disease with many faces. In: Hoehn H., and Schindler D. (Eds). Fanconi Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging (2007), Karger, Basel 9-22
133. Toraldo R., Canino G., Tolone C., D'Avanzo M., Porfirio B., Hoehn H., Schroeder-Kurth T., and Pistoia V. Variable response to the diepoxybutane test in two dizygotic twins with Fanconi's anemia and flow cytometry for diagnosis confirmation. Pediatr. Hematol. Oncol. 15 (1998) 45-54
134. Dokal I., Chase A., Morgan N.V., Coulthard S., Hall G., Mathew C.G., and Roberts I. Positive diepoxybutane test in only one of two brothers found to be compound heterozygotes for Fanconi's anaemia complementation group C mutations. Br. J. Haematol. 93 (1996) 813-816
135. Mankad A., Taniguchi T., Cox B., Akkari Y., Rathbun R.K., Lucas L., Bagby G., Olson S., D'Andrea A., and Grompe M. Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 107 (2006) 3084-3090
136. Glanz A., and Fraser F.C. Spectrum of anomalies in Fanconi anaemia. J. Med. Genet. 19 (1982) 412-416
137. Kalb R., Neveling K., Hoehn H., Schneider H., Linka Y., Batish S.D., Hunt C., Berwick M., Callen E., Surralles J., Casado J.A., Bueren J., Dasi A., Soulier J., Gluckman E., Zwaan C.M., van Spaendonk R., Pals G., de Winter J.P., Joenje H., Grompe M., Auerbach A.D., Hanenberg H., and Schindler D. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am. J. Hum. Genet. 80 (2007) 895-910
138. Sims A.E., Spiteri E., Sims III R.J., Arita A.G., Lach F.P., Landers T., Wurm M., Freund M., Neveling K., Hanenberg H., Auerbach A.D., and Huang T.T. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat. Struct. Mol. Biol. 14 (2007) 564-567
139. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., and D'Andrea A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 (2002) 606-609
140. Fackenthal J.D., and Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 7 (2007) 937-948
141. Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature 230 (1971) 370-373
142. Popp H., Kalb R., Fischer A., Lobitz S., Kokemohr I., Hanenberg H., and Schindler D. Screening Fanconi anemia lymphoid cell lines of non-A, C, D2, E, F, G subtypes for defects in BRCA2/FANCD1. Cytogenet. Genome Res. 103 (2003) 54-57
143. Rahman N., and Scott R.H. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum. Mol. Genet. 16 (Spec No 1) (2007) R60-66
144. Evers B., and Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25 (2006) 5885-5897
145. Gillio A.P., Verlander P.C., Batish S.D., Giampietro P.F., and Auerbach A.D. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood 90 (1997) 105-110
146. Fabbro M., and Henderson B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp. Cell. Res. 282 (2003) 59-69
147. Huang S., Lee L., Hanson N.B., Lenaerts C., Hoehn H., Poot M., Rubin C.D., Chen D.F., Yang C.C., Juch H., Dorn T., Spiegel R., Oral E.A., Abid M., Battisti C., Lucci-Cordisco E., Neri G., Steed E.H., Kidd A., Isley W., Showalter D., Vittone J.L., Konstantinow A., Ring J., Meyer P., Wenger S.L., von Herbay A., Wollina U., Schuelke M., Huizenga C.R., Leistritz D.F., Martin G.M., Mian I.S., and Oshima J. The spectrum of WRN mutations in Werner syndrome patients. Hum. Mutat. 27 (2006) 558-567
148. Ferrer M., Rodriguez J.A., Spierings E.A., de Winter J.P., Giaccone G., and Kruyt F.A. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Hum. Mol. Genet. 14 (2005) 1271-1281
149. Huck K., Hanenberg H., Gudowius S., Fenk R., Kalb R., Neveling K., Betz B., Niederacher D., Haas R., Gobel U., Kobbe G., and Schindler D. Delayed diagnosis and complications of Fanconi anaemia at advanced age-a paradigm. Br. J. Haematol. 133 (2006) 188-197
150. Yamashita T., Wu N., Kupfer G., Corless C., Joenje H., Grompe M., and D'Andrea A.D. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. Blood 87 (1996) 4424-4432
151. Nookala R.K., Hussain S., and Pellegrini L. Insights into Fanconi anaemia from the structure of human FANCE. Nucleic Acids Res. 35 (2007) 1638-1648
152. Barber L.M., Barlow R.A., Meyer S., White D.J., Will A.M., Eden T.O., and Taylor G.M. Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia. Br. J. Haematol. 130 (2005) 796-797
153. Meyer S., Barber L.M., White D.J., Will A.M., Birch J.M., Kohler J.A., Ersfeld K., Blom E., Joenje H., Eden T.O., and Malcolm Taylor G. Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. Br. J. Haematol. 133 (2006) 284-292
154. Borriello A., Locasciulli A., Bianco A.M., Criscuolo M., Conti V., Grammatico P., Cappellacci S., Zatterale A., Morgese F., Cucciolla V., Delia D., Della Ragione F., and Savoia A. A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia. Leukemia 21 (2007) 72-78
155. Cleton-Jansen A.M., Moerland E.W., Pronk J.C., van Berkel C.G., Apostolou S., Crawford J., Savoia A., Auerbach A.D., Mathew C.G., Callen D.F., and Cornelisse C.J. Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3. Br. J. Cancer 79 (1999) 1049-1052
156. Neveling K., Kalb R., Florl A.R., Herterich S., Friedl R., Hoehn H., Hader C., Hartmann F.H., Nanda I., Steinlein C., Schmid M., Tonnies H., Hurst C.D., Knowles M.A., Hanenberg H., Schulz W.A., and Schindler D. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet. Genome Res. 118 (2007) 166-176
157. Hirsch B., Shimamura A., Moreau L., Baldinger S., Hag-alshiekh M., Bostrom B., Sencer S., and D'Andrea A.D. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103 (2004) 2554-2559
158. Lugthart S., van Drunen E., van Norden Y., van Hoven A., Erpelinck C.A., Valk P.J., Beverloo H.B., Lowenberg B., and Delwel R. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111 (2008) 4329-4337
159. Liu J.M., Buchwald M., Walsh C.E., and Young N.S. Fanconi anemia and novel strategies for therapy. Blood 84 (1994) 3995-4007
160. Hisama F.M., Chen Y.H., Meyn M.S., Oshima J., and Weissman S.M. WRN or telomerase constructs reverse 4-nitroquinoline 1-oxide sensitivity in transformed Werner syndrome fibroblasts. Cancer Res. 60 (2000) 2372-2376
161. Martin G.M., and Oshima J. Lessons from human progeroid syndromes. Nature 408 (2000) 263-266
162. Park Y., and Gerson S.L. DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56 (2005) 495-508
163. Rosselli F., Sanceau J., Gluckman E., Wietzerbin J., and Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood 83 (1994) 1216-1225
164. Pedersen M., Bruunsgaard H., Weis N., Hendel H.W., Andreassen B.U., Eldrup E., Dela F., and Pedersen B.K. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech. Ageing Dev. 124 (2003) 495-502
165. Gupta S., and Gollapudi S. Molecular mechanisms of TNF-alpha-induced apoptosis in aging human T cell subsets. Int. J. Biochem. Cell. Biol. 37 (2005) 1034-1042
166. Li J., Sejas D.P., Zhang X., Qiu Y., Nattamai K.J., Rani R., Rathbun K.R., Geiger H., Williams D.A., Bagby G.C., and Pang Q. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J. Clin. Invest. 117 (2007) 3283-3295
167. D'Andrea A.D. Cellular function of the Fanconi anemia pathway. Nat. Med. 7 (2001) 1259-1260
168. Thami G.P., and Garg G. Cafe-au-lait macules: are these markers of neoplasia of genetic origin?. Dermatology 208 (2004) 234-235
169. De Raedt T., Maertens O., Chmara M., Brems H., Heyns I., Sciot R., Majounie E., Upadhyaya M., De Schepper S., Speleman F., Messiaen L., Vermeesch J.R., and Legius E. Somatic loss of wild type NF1 allele in neurofibromas: comparison of NF1 microdeletion and non-microdeletion patients. Genes Chromosomes Cancer 45 (2006) 893-904
170. Maertens O., Brems H., Vandesompele J., De Raedt T., Heyns I., Rosenbaum T., De Schepper S., De Paepe A., Mortier G., Janssens S., Speleman F., Legius E., and Messiaen L. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum. Mutat. 27 (2006) 1030-1040
171. Martin G.M. Proliferative homeostasis and its age-related aberrations. Mech. Ageing Dev. 9 (1979) 385-391
172. Wajnrajch M.P., Gertner J.M., Huma Z., Popovic J., Lin K., Verlander P.C., Batish S.D., Giampietro P.F., Davis J.G., New M.I., and Auerbach A.D. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics 107 (2001) 744-754
173. Giri N., Batista D.L., Alter B.P., and Stratakis C.A. Endocrine abnormalities in patients with Fanconi anemia. J. Clin. Endocrinol. Metab. 92 (2007) 2624-2631
174. Sherafat-Kazemzadeh R., Mehta S.N., Care M.M., Kim M.O., Williams D.A., and Rose S.R. Small pituitary size in children with Fanconi anemia. Pediatr. Blood Cancer 49 (2007) 166-170
175. Trivin C., Gluckman E., Leblanc T., Cousin M.N., Soulier J., and Brauner R. Factors and markers of growth hormone secretion and gonadal function in Fanconi anemia. Growth Horm. IGF Res. 17 (2007) 122-129
176. Wu J.M., Zelinski M.B., Ingram D.K., and Ottinger M.A. Ovarian aging and menopause: current theories, hypotheses, and research models. Exp. Biol. Med. (Maywood) 230 (2005) 818-828
177. Santoro N., Banwell T., Tortoriello D., Lieman H., Adel T., and Skurnick J. Effects of aging and gonadal failure on the hypothalamic-pituitary axis in women. Am. J. Obstet. Gynecol. 178 (1998) 732-741
178. Welt C.K., Smith P.C., and Taylor A.E. Evidence of early ovarian aging in fragile X premutation carriers. J. Clin. Endocrinol. Metab. 89 (2004) 4569-4574
179. Sandhu S.K., and Sekeres M.A. Myelodysplastic syndromes: more prevalent than we know. Geriatrics 63 (2008) 10-17
180. Alter B.P., Greene M.H., Velazquez I., and Rosenberg P.S. Cancer in Fanconi anemia. Blood 101 (2003) 2072
181. van Zeeburg H.J., Snijders P.J., Pals G., Hermsen M.A., Rooimans M.A., Bagby G., Soulier J., Gluckman E., Wennerberg J., Leemans C.R., Joenje H., and Brakenhoff R.H. Generation and molecular characterization of head and neck squamous cell lines of Fanconi anemia patients. Cancer Res. 65 (2005) 1271-1276
182. Rosenberg P.S., Socie G., Alter B.P., and Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 105 (2005) 67-73
183. Hakim F.T., Flomerfelt F.A., Boyiadzis M., and Gress R.E. Aging, immunity and cancer. Curr. Opin. Immunol. 16 (2004) 151-156
184. van den Biggelaar A.H., Huizinga T.W., de Craen A.J., Gussekloo J., Heijmans B.T., Frolich M., and Westendorp R.G. Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Exp. Gerontol. 39 (2004) 1407-1414
185. Fagerlie S.R., and Bagby G.C. Immune defects in Fanconi anemia. Crit. Rev. Immunol. 26 (2006) 81-96
186. Smith D.W.E. Human Longevity (1993), Oxford University Press, New York, Oxford pp. 84-85
187. Hasty P., Campisi J., Hoeijmakers J., van Steeg H., and Vijg J. Aging and genome maintenance: lessons from the mouse?. Science 299 (2003) 1355-1359
188. Monnat Jr. R.J. From broken to old: DNA damage, IGF1 endocrine suppression and aging. DNA Repair (Amst.) 6 (2007) 1386-1390
189. Garinis G.A., Patil C.K., and Schumacher B. "The molecular basis of aging": the Boehringer Ingelheim Fonds 95th International Titisee Conference. Mech. Ageing Dev. 128 (2007) 469-475
190. Niedernhofer L.J. Tissue-specific accelerated aging in nucleotide excision repair deficiency. Mech. Ageing Dev. 129 (2008) 408-415
191. Niedernhofer L.J., and Robbins P.D. Signaling mechanisms involved in the response to genotoxic stress and regulating lifespan. Int. J. Biochem. Cell Biol. 40 (2008) 176-180
192. Levran O., Diotti R., Pujara K., Batish S.D., Hanenberg H., and Auerbach A.D. Spectrum of sequence variations in the FANCA gene: an International Fanconi Anemia Registry (IFAR) study. Hum. Mutat. 25 (2005) 142-149
193. Gross M., Hanenberg H., Lobitz S., Friedl R., Herterich S., Dietrich R., Gruhn B., Schindler D., and Hoehn H. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet. Genome Res. 98 (2002) 126-135
194. Xia B., Dorsman J.C., Ameziane N., de Vries Y., Rooimans M.A., Sheng Q., Pals G., Errami A., Gluckman E., Llera J., Wang W., Livingston D.M., Joenje H., and de Winter J.P. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39 (2007) 159-161
195. Levran O., Attwooll C., Henry R.T., Milton K.L., Neveling K., Rio P., Batish S.D., Kalb R., Velleuer E., Barral S., Ott J., Petrini J., Schindler D., Hanenberg H., and Auerbach A.D. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet. 37 (2005) 931-933
196. Faivre L., Portnoi M.F., Pals G., Stoppa-Lyonnet D., Le Merrer M., Thauvin-Robinet C., Huet F., Mathew C.G., Joenje H., Verloes A., and Baumann C. Should chromosome breakage studies be performed in patients with VACTERL association?. Am. J. Med. Genet. A 137 (2005) 55-58
197. Holden S.T., Cox J.J., Kesterton I., Thomas N.S., Carr C., and Woods C.G. Fanconi anaemia complementation group B presenting as X linked VACTERL with hydrocephalus syndrome. J. Med. Genet. 43 (2006) 750-754
198. Wagner J.E., Tolar J., Levran O., Scholl T., Deffenbaugh A., Satagopan J., Ben-Porat L., Mah K., Batish S.D., Kutler D.I., MacMillan M.L., Hanenberg H., and Auerbach A.D. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103 (2004) 3226-3229